Warburg Research set a €80.00 ($95.24) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report sent to investors on Monday. The firm currently has a buy rating on the stock.

Several other analysts have also weighed in on the stock. Commerzbank set a €85.00 ($101.19) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Monday, November 6th. Kepler Capital Markets set a €63.00 ($75.00) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Tuesday, November 28th. HSBC set a €70.00 ($83.33) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Wednesday, November 22nd. Deutsche Bank set a €83.00 ($98.81) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Friday, December 1st. Finally, Bank of America set a €75.00 ($89.29) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of €78.66 ($93.65).

Shares of Fresenius SE & Co KGaA (FRA FRE) opened at €65.02 ($77.40) on Monday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($71.62) and a 12-month high of €80.00 ($95.24). The firm has a market cap of $35,910.00 and a PE ratio of 20.71.

TRADEMARK VIOLATION NOTICE: “Fresenius SE & Co KGaA (FRE) Given a €80.00 Price Target at Warburg Research” was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/fresenius-se-80-00-price-target-at-warburg-research/1803697.html.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.